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ABSTRACT 
Paraneoplastic Ma Family (PNMA) comprises a growing number of family members 
which share relatively conserved protein sequences encoded by the human genome and is 
localized to several human chromosomes, including the X-chromosome.  Based on sequence 
analysis, PNMA family members share sequence homology to the Gag protein of LTR 
retrotransposon, and several family members with aberrant protein expressions have been 
reported to be closely associated with the human Paraneoplastic Disorder (PND). In addition, 
gene mutations of specific members of PNMA family are known to be associated with human 
mental retardation or 3-M syndrome consisting of restrictive post-natal growth or dwarfism, 
and development of skeletal abnormalities.  Other than sequence homology, the physiological 
function of many members in this family remains unclear. However, several members of this 
family have been characterized, including cell signalling events mediated by these proteins 
that are associated with apoptosis, and cancer in different cell types. Furthermore, while 
certain PNMA family members show restricted gene expression in the human brain and 
testis, other PNMA family members exhibit broader gene expression or preferential and 
selective protein interaction profiles, suggesting functional divergence within the family.  
Functional analysis of some members of this family have identified protein domains that are 
required for subcellular localization, protein-protein interactions, and cell signalling events 
which are the focus of this review paper. 
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1. Introduction 
Paraneoplastic Ma Antigen (PNMA) family is represented by at least fifteen family members,  
and three of the family members, PNMA1-3, are known to be associated with the 
Paraneoplastic Disorder (PND)[1–8]. Recent human genome sequence analysis has identified 
additional members that belong to this family and a total of nineteen family members are 
currently known to be encoded by the human genome [9,10]  The patients of PND associated 
with PNMA1-3 were reported to exhibit syndromes consisting of paraneoplastic limbic and 
brain stem encephalitis , production of auto-antibodies specific to PNMA 1, 2 or 3 as well as 
cancer [1,3,11–16]. Molecular diagnostic methodologies are  often used to diagnose PND, 
including detection of auto- antibodies against PNMA proteins as well as identification of 
aberrantly expressed PNMA 1, 2 or 3 in the tumor tissues [5,17,18]. Although the mechanism 
that contributes to development of PND is unclear, its likely to be associated with aberrant 
expressions of PNMA1, 2 or 3 in tumor cells originated from non-neuronal tissues, including 
lung, breast and testicular tumors, leading to the development of tumor immunity against 
PNMA1, 2, or 3 [19–24].    In normal individuals, PNMA family members are predominantly 
expressed in the human brain, and testis, except for MOAP-1 (PNMA4), and CCDC8 which 
are ubiquitously expressed in many human tissues and higher MOAP-1 expression is detected 
in the human brain and heart [5,8,25–27]. Among the PNMA family members, MOAP-1 is 
the most extensively studied protein in the family. MOAP-1 was reported to mediate 
apoptotic signalling by interacting with Bax, a pro-apoptotic member of Bcl-2 family[8,28–
35]. Furthermore, MOAP-1 was shown to interact with RASSF1A tumor suppressor through 
TNF receptor mediated signalling upon activation of the TNF receptor by TNF ligand [28–
31,36–39]. Other than PND, genetic mutations of two other PNMA family members are 
known to be associated with restrictive human growth and mental retardation [25,40]. This 
paper describes current information on some members of the PNMA family members that are 
relatively well characterized, including their roles in cancer and apoptotic signalling. 
2. Chromosomal Localization and Gene Structure 
PNMA family members are encoded by at least 15 genes localized to human chromosome 14 
(PNMA1 and MOAP-1), chromosome 19 (PNMA8A-C, and CCDC8), chromosome 8 
(PNMA2), and X chromosome (PNMA3, PNMA5, and PNMA6A, PNMA6B, PNMA6E, 
PNMA6F, PNMA7A, and PNMA7B, Table 1). In addition, three additional PNMA family 
members, PNMA6E, 6F, and 8C which are likely to be generated through gene duplication 
events, were identified after analysis of the human genome databases (GRCh37.p5, 
GRCh38.p10 [41]).    In addition, extensive annotations of the human genome database 
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(GRCh38.p10) has resulted in reclassification of some of the PNMA members, PNMA6C, 
and PNMA6D, as existing members of the PNMA family, PNMA6A, and PNMA6B, 
respectively (Table 1,[42,43]), as well as identification of pseudogenes that do not belong to 
the PNMA family (Table 2) . Furthermore, among the PNMA gene family, PNMA6B is 
classified as unprocessed pseudogene without protein coding function [43]. It is interesting to 
know that although most PNMA family members are expressed from multiple exons, the 
coding sequences of PNMA family members are mostly encoded by a single exon (Table 1), 
raising the possibility that the expression of PNMA family members may be regulated 
through other cellular mechanisms. Indeed, MOAP-1 is known to be regulated by miRNAs as 
well as proteasome pathway [30,44,45]. 
 
3. Sequence Homology 
 
PNMA family members share high protein sequence homology with the highest sequence 
homology of 84% between PNMA7A and PNMA7B (Figure 1). The lowest protein sequence 
homology of 9.5% is between PNMA7A and CCDC8 (Figure 1). PNMA family members 
share high sequence homology at the N-terminal conserved domain (NCD), except 
PNMA7A, and PNMA7B (Figure 2). The other conserved domain of the PNMA family 
members is the central conserved domain (CCD), except PNMA8A-C, which show 
significant sequence divergence within this region (Figure 2). Situated between NCD and 
CCD domains are unique protein sequence or domain (UPD) found in some members of 
PNMA including the BH3-like (BH3-L) domain of MOAP-1 and PNMA1 (Figure 2-3). In 
addition, a region rich in Lysine and Arginine basic residues, and designated as KRs is found 
in the protein sequences of all the members of PNMA family, except PNMA8B, and 
PNMA8C.  Furthermore, it is interesting to know that PNMA family members share 
sequence homology at a poly-glutamic acid rich region (PolyE) near the C-terminus, except 
PNMA6F, 8A, and 8C (Figure 3A-B).  Beyond the poly-glutamic acid rich region is the C-
terminus with varying length and low sequence homology (variable C-terminal sequence, 
VCS) that can be identified in the protein sequences among the PNMA family members. 
Nuclear targeting signal of PNMA5 was identified in the VCS region of PNMA5, PNMA7A 
and PNMA7B (Figure 3A-B). From the sequence analysis, PNMA family members are 
conserved in quite a number of species, including rat, mouse, monkey, and chimpanzee 
[4,41].  Further sequence analysis has shown that PNMA family members are conserved in 
chimpanzee and mouse with the lowest and highest amino acid sequence identity between 
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56% and 99% (Table 1), with the exception of PNMA6A, PNMA8A and PNMA8B which 
are found only in human and chimpanzee, but not in mouse, based on sequence analysis using 
the Blast tool of Ensembl [43]. Similarly, human PNMA6E shares significant amino acid 
sequence homology (64%) to mouse PNMA6E (Gm18336) and 77% of the sequence 
homology with chimpanzee PNMA6F. Although sharing high sequence homology, functional 
diversifications of PNMA family members have been reported [46,47]. It is likely that the 
functional diversifications stem from variation in amino acid sequences of the PNMA family 
members, particularly from the UPD and VCS regions, as evidenced by the presence of BH3-
like domain of MOAP-1 in the UPD region, and nuclear localization signal of PNMA5, 
PNMA7A, and PNMA7B in the VCS region, respectively. In addition, based on sequence 
alignment, PNMA family members exhibit significant homology to Gypsy12_DR Gag 
protein of LTR retrotransposon, suggesting PNMA family members are derived from LTR 
retrotransposon with common origins in Eutherians and Marsupials [9,10,41].  
 
4. Protein-Protein Interactions 
 
4.1 Interaction with Bcl-2 family Members 
MOAP-1, also known as MAP-1, is the most extensively studied protein in the family. 
MOAP-1 is a 39.5 kDa novel molecule identified through interaction with Bax, a pro-
apoptotic member of Bcl-2 family [8,32]. Deletion mapping and mutagenesis studies showed 
that MOAP-1 interacts with Bax through its BH3-like domain, which shows significant 
sequence homology to BH3 domains of pro-apoptotic molecules of the Bcl-2 family. The 
BH3- domain of Bcl-2 family plays a critical role in mediating apoptotic signalling as 
highlighted by the presence of BH3-only pro-apoptotic molecules which are involved in 
apoptosis signalling through interactions with multi-domain pro-apoptotic as well as pro-life 
molecules of the Bcl-2 family[48–57]. Structural information derived from X-ray 
crystallography and NMR studies of Bax in complex with the BH3 domain of pro-apoptotic 
molecules such as Bim and Bid have been determined and the data show the important role of 
BH3-domain of Bim and Bid in promoting activation of Bax through binding to Bax by 
inducing change in conformation of Bax, leading to exposures of the BH3 domain as well as 
C-terminal domain (α6- α8) of Bax [54,58–62]. Once exposed, Bax BH3 and the C-terminal 
domains engage neighbouring Bax monomer to generate Bax dimers, and oligomers 
[49,58,59,62]. Furthermore, change in the Bax conformation enables C-terminus of Bax (α9) 
to be associated with mitochondrial membrane, effectively anchoring Bax oligomers to 
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mitochondria, leading to mitochondrial dysfunction and release of mitochondrial cytochrome 
C [58,59]. Although required for binding to Bax, deletion mapping studies have shown that 
the BH3-like domain of MOAP-1 is not required for MOAP-1 to interact with Bcl-XL, which 
interacts with the N- and C-terminal regions of MOAP-1[8,32,34]. Due to its pro-apoptotic 
activity, Bax is known to be frequently mutated in cancer cells [63–66].  
 
 
 
4.2 Interaction with transcription factors and growth factors  
Other than MOAP-1, PNMA7A (ZCCHC12, SIZN1) which shares 32% amino acid sequence 
identity with MOAP-1 was reported to function as transcriptional co-activator and participate 
in Bone Morphogenic Protein (BMP) signalling by interacting with Smad1 and CBP [43]. 
Other than BMP cell signalling, PNMA7A was identified as transcriptional co-activator that 
interacts with c-Jun and activates AP-1 and CREB signalling [67]. Like many members of 
PNMA family, PNMA7A was found to be predominantly expressed in mouse brain, 
including cholinergic neurons as well as testis, pointing to the possibility that PNMA7A 
could play an important role in the developmental regulation or maintenance of neuronal cells 
[68]. In addition, mutations of PNMA7A were found to be associated with human mental 
retardation [40,69]. Currently, it’s not clear whether PNMA7A plays a role in neuronal 
survival or apoptosis; however, recent studies showed that PNMA7A functions as an 
oncogene and the expression is elevated in thyroid cancer cells [70,71], suggesting than 
PNMA7A could function to promote neuronal and cancer cell growths.  The coiled coil 
domain containing molecule, CCDC8, was one of the candidate genes identified to play a 
crucial role in human growth. Mutations of CCDC8 gene were associated with post-natal 
growth restriction, one of the well described features of  3M-syndrome [25,72]. Other than 
CCDC8 mutations in two other human genes, CUL7 and OBSL1, were also reported to be the 
important contributing factors of 3M-syndrome[72]. Interestingly, OBSL-1 was found to be 
the common protein interacting partner of both CCDC8 and CUL7, suggesting that the 
molecules might participate in common cell signalling pathway that regulate human 
growth[25]. In fact, patients with 3-M syndrome were found to exhibit growth hormone 
deficiency or disordered growth factor signalling [73,74].  Furthermore, protein expression 
studies showed that CCDC8 protein level is relative low in tumour cells, and over-expression 
of CCDC8 in cancer cells inhibits invasiveness and metastasis of cancer cells [75]. 
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4.3 Interaction with death receptors associated signalling molecules and RASSF family 
members 
   Other than interacting with Bcl-2 family members, MOAP-1 was reported to be associated 
with RASSF1A, and RASS6 [29,76–78]. RASSF1A is a tumor suppressor and its protein 
expression is frequently silenced in many cancer cells through hyper-methylation of its gene 
promoter [37,79–84]. Deletion and site directed mutagenesis studies showed that MOAP-1 
interacts with poly-glutamic acid residues of RASSF1A [30,85,86]. In addition, MOAP-1 
was shown to interact with RASSF1A, and TNF-R through its RASSF1A binding domain 
within the KRs region and poly-glutamic acid rich residues (polyE) of its C-terminus, 
respectively. Other than interacting with TNF-R1, MOAP-1 was reported to interact with 
TRAIL-R1 [86]. MOAP-1 was reported to be present in an inactive conformation through 
intramolecular interaction, and by interacting with RASSF1A,  MOAP-1 is unfolded with its 
exposed BH3-like domain to interact and promote Bax activation, leading to transmigration 
of activated Bax to the mitochondria [30,85,86]. Other than RASSF1A, MOAP-1 was 
reported as MTCH2 interacting protein and plays an important role in Fas receptor mediated 
apoptosis signalling by promoting recruitment of tBid to the mitochondria during 
apoptosis[87].  
 
 
 
 
4.4 Protein-protein interaction among the PNMA family members 
In addition, MOAP-1 was reported to interact with its family members, including PNMA2, 
and PNMA5 [46,47]. Interaction with PNMA2 leads to inhibition of pro-apoptotic function of 
MOAP-1. In contrast, interaction with PNMA5 enhances pro-apoptotic function of MOAP-1. 
Furthermore, although sharing relatively high sequence homology, interaction between 
MOAP-1 and PNMA1 was not detectable in co-immunoprecipitation  studies [46]. In 
addition, it is likely that PNMA family members may interact with other cellular proteins that 
modulate its activity or promote activation of activity that leads to stimulation of cell growth 
such as the aberrantly expressed PNMA1-3 in cancer cells (Figure 4). 
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5. Protein Domains and Cell Signalling  
5.1 Apoptosis Signalling of PNMA family members 
Although MOAP-1 (PNMA4) was reported to mediate apoptosis by interacting with Bcl-2 
family members, and RASSF protein isoforms, other PNMA family members are not known 
to be associated with these molecules, suggesting functional divergence among the PNMA 
family members[8,32]. In the absence of non-apoptotic stimuli, MOAP-1 is held in inactive 
conformation where the BH3-like domain of MOAP-1 is buried. This ‘closed’ confirmation 
is mediated via electrostatic interactions between the 178EEEF and 202KRRR motifs of 
MOAP-1 [34]. Similar to MOAP-1, Bid, a pro-apoptotic member of Bcl-2 family was 
reported to be held in inactive conformation through intramolecular interaction between the 
BH3 and BH3-like domains of Bid[55].  
Activation of MOAP-1 requires death stimuli, RASSF1A or RASSF6, in the presence of K-
RAS to promote or enhance apoptotic signalling through change of MOAP-1 conformation, 
leading to exposure of MOAP-1 BH3-like domain, which interacts with the pro-apoptotic 
Bax, resulting in activation of apoptotic cell death [30,39]. The pro-apoptotic Bid is similarly 
activated through cleavage of the N-terminus domain, leading to exposure of its BH3 domain 
that promotes apoptotic signalling, including interactions with   pro-life and pro-death 
members of Bcl-2 family[55]. In addition, mouse xenograft experiments showed that 
expression of both MOAP-1 and MOAP-1 interacting molecule, RASSF1A, in cancer cells 
produce additive effect in tumor suppression better than individually expressed MOAP-1 or 
RASSF1A  [88]. Furthermore, MOAP-1 knockout mouse model showed that MOAP-1 
participates in Fas receptor mediated apoptosis by interacting with MTCH2 to facilitate 
recruitment of tBid to the mitochondria through two regions of MOAP-1 (aa 120-162 and 
253-293), including the critical amino acid residues (120L, and 125GHE) within the BH3-like 
domain of MOAP-1,which lends further support to the important role of MOAP-1 in 
apoptosis signalling through mitochondria signalling pathway [87]. 
     Similar to MOAP-1, PNMA1 was reported to mediate apoptotic cell death of cerebellar 
granule neurons (CGN) , which requires the N-terminal region of PNMA1 containing a BH3-
like domain[6,89]. However, the BH3-like domain of PNMA1 is not known to be associated 
with pro-apoptotic Bax, and it is possible that it may interact with an un-identified member of 
the Bcl-2 family as apoptosis mediated by PNMA1 can be inhibited by over-expression of 
Bcl-2 in the neuronal cells even no direct interaction between PNMA1 and Bcl2 has been 
observed, suggesting that Bcl2 indirectly inhibits PNMA1 by sequestering the BH3-like 
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domain-binding molecule of PNMA1 [89]. Further evidence shows that PNMA1 expression 
is elevated in the striatum of mouse model of Huntington’s disease, suggesting that PNMA1 
expression plays an important role in neuro-degeneration by inducing neuronal cell death in 
Huntington’s disease model[89]. The nuclear localization signal (NLS) of PNMA7A plays an 
important role for protein translocation to nucleus where PNMA7A was reported to function 
as transcriptional activator by interacting with Smad1 and CBP in BMP mediated cell 
signalling [25]. In addition, PNMA7A was found to activate AP-1 and CREB, and interacts 
with C-Jun through its nuclear targeting function [67]. 
5.2 Anti-apoptosis cell signalling and cancer   
  PNMA2, an onconeuronal antigen, was reported to be aberrantly expressed in a number of 
tumors, and its over-expression is likely to be closely associated with tumorigenesis 
[5,14,15,46,90–100]. However, other than closely associated with paraneoplastic disease, the 
molecular function of PNMA2 remains unclear. In order to identify the potential function of 
PNMA2, over-expression studies were conducted which showed that unlike PNMA1 and 
MOAP-1, over-expressed PNMA2 failed to promote apoptotic signalling in transfected MCF-
7 cells. However, PNMA2 was shown to interact with both PNMA1 and MOAP-1 in co-
immunoprecipitation studies, as well as functionally antagonized the pro-apoptotic function 
of both MOAP-1 and PNMA1[46]. The functional domain of PNMA2 involved in interaction 
with PNMA1 and MOAP-1 has not been identified. In contrast, the N-terminal domain (aa 1-
315) of MOAP-1 was reported to be required to interact with PNMA5, and transient co-
expression of MOAP-1 and PNMA5 synergistically enhanced apoptotic signalling in 
transfected cancer cells. The C-terminal domain of PNMA5 (aa 316-448) contains a NLS that 
is required for nuclear localization of PNMA5. Both the N-terminal and C-terminal domains 
of PNMA5 are required for apoptotic signalling in cancer cells [47]. Other than PNMA5, 
functional characterization of CCDC8 showed that over-expressed CCDC8 inhibited 
invasiveness of A549 cells while CCDC8 knock-downed cells promoted invasiveness of the 
cancer cells in cell migration assay [75], suggesting that CCDC8 is a pro-apoptotic protein. In 
contrast,   ZCCHC12 was found over-expressed in papillary thyroid tumours and ZCCHC12 
knocked downed thyroid cancer cell lines exhibited reduced number of colonies formed in 
the colony formation assay [70,71], providing further evidence to support that ZCCHC12 
functioned as an oncogene in papillary thyroid cancer [71]. 
 
6. Regulation of PNMA family Members 
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6.1 Regulation by ubiquitination and protein degradation 
MOAP-1 has a short half-life of 25 min and the stability of the protein is regulated through 
ubiquitin proteasome pathway in which degradation of MOAP-1 occurred at G1, and S-G2 
phases of cell cycle by the APC/CCdh1 and the UBR5 ubiquitin ligases, respectively[101–
103]. In contrast, Trim39 ubiquitin ligase interacts with MOAP-1 and promotes stability of 
MOAP-1 by inhibiting the activity of  APC/CCdh1-mediated ubiquitination and 
degradation[104,105]. Due to its short half-life, the endogenous level of MOAP-1 in cancer 
cell lines was shown to be  relatively low; however, MG-132, a proteasome inhibitor, could 
significantly enhance the stability and level of MOAP-1 protein in cancer cells[103].  
6.2 Regulation by miRNA 
Although the exact mechanism has not been identified, MOAP-1 protein level was enhanced 
or stabilized in the cancer cells when treated with chemo-drugs or apoptosis stimuli[103]. 
One possible explanation for stabilization of MOAP-1 during drug-induced apoptosis in 
cancer cells is the down-regulation of miRNA-1228 expression level during drug 
treatment[44]. miRNA-1228 negatively regulates MOAP-1 expression by binding to the 
miRNA target sequence of the MOAP-1 mRNA, and down-regulation of miRNA-1228 was 
shown to promote MOAP-1 stabilization [44]. Similarly, miR-25 has been reported to 
promote cell proliferation by promoting down-regulation of MOAP-1 expression in lung 
cancer [45]. 
 
6.3 Regulation by other mechanisms 
In addition, MOAP-1 may be regulated by phosphorylation as several phosphorylation sites 
have been identified in MOAP-1 protein sequence [29]. Analysis of MOAP-1 gene led to the 
identification of CpG island located near the gene promoter of MOAP-1, pointing to the 
possibility that MOAP-1 might be regulated through hyper-methylation of its gene promoter 
[106]. Other than gene expression regulation, pro-apoptotic activity of MOAP-1 was reported 
to be regulated by members of PNMA family. Co-expression of MOAP-1 with PNMA2 
resulted in inhibition of pro-apoptotic activity of MOAP-1 in transiently transfected cancer 
cells[46]. Interestingly, PNMA2 has been shown to antagonize both pro-apoptotic activities 
of MOAP-1 and PNMA1 through heterodimeric interaction with MOAP-1 and PNMA1[46]. 
In contrast, co-expression of MOAP-1 with PNMA5 significantly enhanced pro-apoptotic 
activity of MOAP-1 in transfected cancer cells [47]. Similar to MOAP-1, CCDC8 was found 
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to be hyper-methylated or epigenetically silenced in breast tumors that showed metastasis 
potential [107]. In addition, CCDC8 knock-downed cancer cells showed increase in 
migration potential when tested in cell migration assay [75]. Regulation of other PNMA 
family members is currently unknown. 
 
Concluding Remarks 
    PNMA family is represented by at least fifteen family members encoded by the human 
genome, and many family members share relatively conserved amino acid sequences near the 
N-terminal domain, whereas the C-terminal domain of some of the family members are 
functionally diverse, which includes nuclear localization signal and DNA binding domain. 
Although sharing relatively conserved amino acid sequence, some members of the PNMA 
family exhibit functional divergence, including members that are agonist or antagonist of 
apoptosis signalling when expressed in cancer cells. Its likely that the PNMA family 
represents a novel set of proteins that are involved in regulation of cell growth, apoptosis, or 
cell fate determination in different cell types, including brain, testis, and heart where PNMA 
family members have been shown to express at relatively high levels. Further investigations 
are required to determine functional relationship of other PNMA members, and their specific 
role in human cells which could lead to a better understanding of the functions of PNMA 
family. 
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Figure Legend 
Figure 1: Sequence Comparisons. Sequence comparisons were carried out using MUSCLE 
sequence alignment software to identify sequence homology based on percent identity of 
amino acid sequences between members of PNMA family. Percent sequence homology 
greater than 40% are highlighted in bold. 
 
Figure 2: Sequence Alignment of PNMA family members.  Unitprot amino acid sequences 
of PNMA family members were aligned using T-Coffee and Clustal W sequence alignment 
programs, and conserved sequences were high-lighted in black using Box Shade software. 
Identity of unitprot protein sequences, Q96BY2(MOAP1), Q8ND90 (PNMA1), Q9UL42 
(PNMA2), Q9UL41(PNMA3), Q96PV4(PNMA5), P0CW24(PNM6A), 
A0A0J9YXQ4(PMA6E), A0A0J9YX94(PMA6F), Q6PEW1(ZCH12), P0CG32(ZCC18), 
Q86V59(PNM8A), Q9ULN7-5(PNM8B), A0A1B0GUJ8(PNM8C), Q9H0W5(CCDC8). 
 
Figure3: Schematic representation and conserved domains of PNMA family members. A. 
Conserved domains identified in the protein sequences of PNMA family members are 
highlighted based on Unitprot amino acid sequences presented in Figure 2. B. General 
structure of PNMA family member.  NCD, N-terminal Conserved Domain; UPD, Unique 
Protein Domain; CCD, Conserved Central Domain (CCD-a, CCD-b, and CCD-c); KRs, KR-
rich sequence, PolyE, Poly-Glutamic Acid Sequence; VCS, Variable C-terminal Sequence, 
NLS, nuclear localization sequence, *NLS, putative nuclear localization sequence. 
 
Figure 4: Schematic representation of MOAP-1 interaction network and cell signalling. 
Reported interactions of MOAP-1 were identified through protein-protein interaction assays, 
including co-immunoprecipitation, and GST-pull down assays. Cell signalling pathways 
mediated by the protein-protein interactions are highlighted. 
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Table 1: Chromosomal localization and gene structure of PNMA family members* 
Protein Protein Name Chromosome 
Location 
(GRCh38.p10) 
and Name of 
Transcript 
Exon Intron Number of 
amino acids 
Protein 
coding 
in 
single 
exon 
Homologues in other 
species, Chimpanzee 
(C) and Mouse (M), % 
amino acid identity 
 
P1 PNMA1 14:73711783-
73714372; 
PNMA1-201 
1 0 353 Yes  C (99%) 
 M (76%) 
P2 PNMA2 8:26504686-
26514092; 
PNMA2-204 
3 2 364 Yes  C (100%) 
 M (92%) 
P3 PNMA3 X:153057036-
153058467; 
PNMA3-202 
1 0 463 Yes  C (99%) 
 M (72%) 
P4 PNMA4 (MOAP1) 14:93,182,199-
93,184,923 
MOAP1-202 
2 1 351 Yes  C (99%) 
 M (76%) 
P5 PNMA5 X:152988824-
152992214; 
PNMA5-201 
2 1 448 Yes  C (98%) 
 M (56%) 
P6 PNMA6A/ 
PNMA6C 
X:153072482-
153075018; 
PNMA6A-201 
2 1 399 Yes  C (99%) 
P7 PNMA 6B 
/PNMA6D 
X:153075769-
153076968; 
PNMA6B-201 
1 0 No Protein; 
Unprocessed 
Pseudogene 
N/A  N/A 
P8 PNMA6E X:153,396,906-
153,401,420 
PNMA6E-201 
2 1 647 Yes  M (64%) 
P9 PNMA6F X:153317681-
153321822; 
PNMA6F-201 
2 1 578 Yes  C (99%) 
 M (65%) 
P10 PNMA7A/ 
ZCCHC12/SIZN1 
X:118823790-
118826968; 
ZCCHC12-201 
4 3 402 Yes  C (99%) 
 M (75%) 
P11 PNMA7B/ 
ZCCHC18 
X:104,112,511-
104,115,604 
ZCCHC18-203 
2 1 403 Yes  C (92%) 
 M (68%) 
P12 PNMA8A/ 
PNMAL1 
19:46,466,498-
46,471,563 
PNMA8A-201 
3 2 439 No (2 
Exons) 
 C (99%) 
 
P13 PNMA8B/ 
PNMAL2 
19:46,491,191-
46,496,498; 
PNMA8B-202 
1 0 635 Yes  C (98%) 
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*Information derived from HGNC (HUGO Gene Nomenclature Committee), Uniprot, and Ensembl. 
Transcript name is based on information provided by Ensembl genome browser based on human 
genome assembly, GRCh38.p10. 
  
P14 PNMA8C 19:46,424,697-
46,428,951; 
PNMA8C-201 
1 0 204 Yes  C (99%) 
 M (74%) 
P15 CCDC8 19:46410372-
46413584; 
CCDC8-201 
1 0 538 Yes  C (99%) 
 M (62%) 
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hsPNMA 
No. 
Genomic 
location in 
GRCh37.p5 
 
Genomic 
location in 
GRCh38.p10 
 
Overlapping 
genes 
Orientation Length % ID 
7 X: 152584221 –
152587591 
X: 153318763 –
153322133 
PNMA6F Forward 3371 100 
8 X: 152662364 –
152663269 
X: 153396906 –
153397811 
PNMA6E Forward 906 100 
9 X: 152197130 –  
152200901 
X: 153028785 –
153032555 
AC243591.1 Forward 3772 99.68 
     15 19: 47036933 – 
47037357 
19: 46427925 –
46428338 
PNMA8C Forward 414 100 
     16 19: 46931182 –  
46931595 
19: 46533676 –
46534100 
AC011551.1 Forward 425 100 
       
 
Table 2: The genomic repositioning of earlier reported PNMAs 
Table 2 shows the new locations of 5 PNMA family members reported by Iwasaki et al. (2013).  From 
sequence analysis, it was unearthed that hsPNMAs 7, 8 and 16, reported by the earlier group, are 
indeed, PNMAs. However, as can be seen from the table, they are already known by other aliases, 
namely 6F, 6E and 8C, respectively. The query length of the PNMAs covered while doing a BLAT 
analyses of the sequences located in GRCh37.p5 showed 100% match (identity) with those of the 
repositioned PNMAs, thereby validating that the genes encode additional PNMA family members 
which are likely to be generated through gene duplication events. However, the earlier reported 
hsPNMA 9 and 16, are found to be not belonging to the PNMA family. In fact, the earlier PNMA9 has 
been now found to be an unprocessed pseudogene AC243591.1. Similarly, PNMA16 reported earlier 
has now been mapped onto AC011551.1, an unprocessed pseudogene.  
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Highlights For Review 
 Gene structure and protein coding exons of PNMA family members 
 
 Sequence alignment, conserved and non-conserved protein sequences 
 
 Protein domains, and protein-protein interactions of PNMA family members with 
RASSF family members, Bax, TNF-R1, TRAIL-R1, and mitochondrial proteins. 
 
 Regulations of PNMA family members, including ubiquitination, DNA hyper-
methylation, CpG island, phosphorylation, miRNA, and protein interactions 
 
 Cell signalling mediated by PNMA family members, including TNF and TRAIL 
receptor mediated signalling, apoptosis, ubiquitin proteasome, and cancer cell 
signalling pathways. 
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